Latest news
QTTB: Bempikibart shows strong efficacy and safety in severe alopecia areata, supporting Phase 3 advancement - TradingViewTradingView · Wed, 05 Aug 2026 11:39:41 GMTQ32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingViewTradingView · Wed, 05 Aug 2026 11:13:00 GMTQTTB: Strong 36-week efficacy data and $200M financing position support late-stage bempikibart trials - TradingViewTradingView · Wed, 05 Aug 2026 11:11:52 GMTQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TradingViewTradingView · Wed, 05 Aug 2026 10:59:00 GMTBiotech Analysis Central Model 10+ Portfolio #17 Q32 Bio; Positive Bempikibart Part B AA Data, 1st Half 2027 Ph 3 Trial Initiation, Additional Part B Data 2nd Half 2026, And Catalysts (NASDAQ:QTTB) - Seeking AlphaSeeking Alpha · Mon, 03 Aug 2026 18:53:31 GMT